Inhalants: The Substance Class Nobody Talks About
Legal, cheap, and lethal on the first use. Underappreciated in addiction education — especially for kids.
Body — 8 lenses: [Science: solvents act as NMDA antagonists + GABA modulators; nitrites as smooth-muscle relaxants via NO; aerosols variable. Biology: sudden sniffing death syndrome (cardiac sensitization to catecholamines), hypoxia, leukoencephalopathy (toluene), hepatorenal toxicity. Psychology: typically first-used age 9–13, often precedes other substance use; associated with ACEs. Policy: mostly not controlled (volatile solvents legal); age-of-sale laws for specific products; poppers under ambiguous FDA status. Trends: SAMHSA NSDUH tracks; resurgence concerns in some regions. Social: historically framed as “kid’s drug”; underrepresented in most SUD curricula. Treatment: abstinence-based (no meds); family therapy; CRAFT. Harm reduction: never use alone, ventilation, don’t use with CNS depressants, education for parents and schools.]
Sources Cited
- 01.A
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionYouth & Young AdultsFamilies & CaregiversPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.